Connect your AI

Biohaven BHVN Short- term Investments

Short- term Investments at other companies

Xenon PharmaceuticalsXENE

——

Vir Biotechnology, Inc.VIR

——

Roivant SciencesROIV

——

Protagonist TherapeuticsPTGX

——

Vera TherapeuticsVERA

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

Operating income-$130.4M+41.1%

Net income-$130.5M+41.1%

EPS (diluted)-$0.88+59.4%

Balance sheet

Cash & equivalents$277.1M+170%

Total debt$286.2M+706%

Total equity$129.5M-50.1%

Total assets$466.4M+1.6%

Cash flow

Operating cash flow-$149.9M+9.2%

CapEx--100%

Free cash flow-$149.9M+9.5%

Valuation

Market cap$2.23B-48.1%

Enterprise value$2.23B-46.3%

Returns & leverage

Return on equity-333%+17.9pp

Debt / equity2.2×+2.1×

Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Biohaven's short- term investments?: Biohaven (BHVN) reported short- term investments of $74.74M in Q1 2026.
How has Biohaven's short- term investments changed year-over-year?: Biohaven's short- term investments decreased by 66.7% year-over-year, from $224.33M to $74.74M.